How much funding has ATXA Therapeutics raised?

ATXA Therapeutics has raised $2.9M in total funding, most recently a Grant round.

Who are ATXA Therapeutics's investors?

ATXA Therapeutics's investors include European Innovation Council Fund.

When was ATXA Therapeutics founded?

ATXA Therapeutics was founded in 2015.

Where is ATXA Therapeutics headquartered?

ATXA Therapeutics is headquartered in Dublin.

What industry is ATXA Therapeutics in?

ATXA Therapeutics operates in Biotech.

How many employees does ATXA Therapeutics have?

ATXA Therapeutics has 1-10 employees.

ATXA Therapeutics

Dublin · Founded 2015 · $2.9M raised

Biotech

Headquarters: Dublin
Employees: 1–10
Founded: 2015
Business Model: B2B

Website: atxatherapeutics.com
Total Funding: $2.9M
Last Round: $2.9M GrantOct 2018
Rounds: 2

About

ATXA Therapeutics is a Dublin, Ireland-based clinical-stage pharmaceutical company developing novel small-molecule antagonists of the Thromboxane Receptor (TP) for cardiopulmonary diseases. Founded in 2015 by Professor Therese Kinsella as a University College Dublin spin-out, its lead compound NTP42 is in development for pulmonary arterial hypertension and has received Orphan Drug Designation from both the EMA and FDA.

Summary

ATXA Therapeutics is a Biotech company based in Dublin, founded in 2015. It has raised $2.9M in total across 2 rounds, most recently a $2.9M Grant round in Oct 2018. Investors include European Innovation Council Fund.